Multiple preventive & treatment options are now authorized by the FDA for emergency use in outpatient settings. The Pennsylvania Department of Health (PA DOH) can support your facility in accessing these lifesaving products.

### WHAT COVID-19 THERAPEUTICS (Tx) ARE CURRENTLY ALLOCATED BY PA DOH?

<table>
<thead>
<tr>
<th>What are they</th>
<th>Oral antivirals (OAVs)</th>
<th>Monoclonal Antibodies (mAbs) for Treatment</th>
<th>Monoclonal Antibodies for Pre-Exposure Prophylaxis (PrEP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Who should get them¹</td>
<td>Oral medications (pills) that prevent multiplication of the COVID-19 virus and help prevent worsening or progression of illness</td>
<td>Intravenous (IV) infusion of antibodies like those produced naturally during COVID-19 infection, preventing worsening or progression of illness</td>
<td>Intramuscular (IM) injection of antibodies that help neutralize the COVID-19 virus to prevent infection and disease in people with compromised immune systems</td>
</tr>
<tr>
<td>When to get them</td>
<td>Non-hospitalized patients with mild to moderate COVID-19 over 12 years-old (18+ for Lagevrio)</td>
<td>Non-hospitalized patients over 12 years-old when oral antivirals are not available, feasible to use, or clinically appropriate</td>
<td>Immunocompromised patients and those who are not able to be fully vaccinated with any available COVID-19 vaccines due to a history of severe reactions</td>
</tr>
<tr>
<td>Currently EUA authorized Tx</td>
<td>COVID-positive, within the first 5 days of symptom(s) onset</td>
<td>COVID-positive, within first 7 days of symptom(s) onset</td>
<td>COVID-negative, no known exposure</td>
</tr>
<tr>
<td>Paxlovid (Pfizer)</td>
<td>Bebtelovimab² (Eli Lilly)</td>
<td>Evusheld (AstraZeneca)</td>
<td></td>
</tr>
</tbody>
</table>

¹. Federal supply of Bebtelovimab is expected to run out July ’22. Providers are encouraged to prescribe Paxlovid if clinically appropriate.

### HOW CAN MY FACILITY ACCESS THESE COVID-19 THERAPEUTICS?

**If you have your own pharmacy on site and/or the ability to prescribe and dispense Tx in your facility...**

Enroll to be a therapeutics provider with PA DOH
- Complete PA DOH’s [therapeutics enrollment form](#)
- You will need to be a registered Health Partner Ordering Portal (HPOP) user. If you aren’t already, PA DOH can help create your account upon enrollment. **Your facility needs a pharmacy license and/or a licensed medical director to take responsibility**
- See PA DOH’s [COVID-19 therapeutics handbook](#) for more information
- Once you are enrolled, you will receive additional instructions to receive product

**If you use a pharmacy partner that dispenses Tx to you...**

Check if your pharmacy stocks COVID-19 therapeutics
- To check if your pharmacy has product(s), use this [locator tool](#) or call sites listed on PA DOH’s [website](#) to confirm product availability
- If your pharmacy partner does not have product, **inform them of how they can enroll with PA DOH**; send them the link to the [therapeutics enrollment form](#)

### WHERE CAN I FIND ADDITIONAL RESOURCES?

- For more information and the latest updates on COVID-19 therapeutics, please visit: [PA DOH](#), [ASPR](#), [CDC](#), [NIH](#)
- Contact us at [covidtherapeutics@pa.gov](mailto:covidtherapeutics@pa.gov) with any questions

Last updated: 6/22/2022